Cohance Lifesciences secures strong credit rating, approves employee stock options

Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) announced on December 3, 2025, that India Ratings & Research has assigned an 'IND AA/Stable/IND A1+' rating to its INR6,850 million bank loan facilities, reflecting the company's financial stability and strong creditworthiness.

In a separate announcement on the same date, Cohance Lifesciences Limited disclosed the approval and grant of 8,015,626 stock options to eligible employees under its Employee Stock Option Plan 2023 ("ESOP 2023"). Each option grants the right to apply for and be allotted one equity share with a face value of INR1. The ESOP 2023 scheme is in compliance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

The options will vest over a minimum period of one year and a maximum of ten years from the grant date, with an exercise period of up to three years from the date of vesting. These strategic moves underscore Cohance Lifesciences Limited's commitment to both financial prudence and employee incentivization.